Does this key event move Imara Inc.’s stock (Nasdaq: IMRA) in the morning session?
Imara Inc. (Nasdaq: IMRA) is a biotech, clinical-stage firm dedicated to making and selling therapy to treat patients with rare genetic disorders of hemoglobin (Hb). Imara Inc. (Nasdaq: IMRA), shares dropped -32.57% to $16.00 in the early morning session after the company announced findings from its phase 2a IMR-687 clinical trial in adult sickle cell disease […]
